v3.26.1
Segment Information
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Information

11. Segment Information

The Company operates and manages its business as one reportable and operating segment, which is the business of developing therapies for autoimmune diseases. The Company’s chief operating decision maker (CODM) is the chief executive officer, who assesses performance of the segment based on net loss, which includes evaluating the progress of ongoing clinical trials. The measure

of segment assets is reported on the balance sheet as total assets. All long-lived assets are maintained in the United States. The following table contains information on segment profit or loss, including significant segment expenses (in thousands):

 

 

THREE MONTHS ENDED JUNE 30,

 

 

SIX MONTHS ENDED JUNE 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Segment expenses:

 

 

 

 

 

 

 

 

 

 

 

 

       AB-101 (AlloNK)

 

 

11,861

 

 

 

8,686

 

 

 

21,793

 

 

 

16,342

 

       Other programs(a)

 

 

18

 

 

 

—

 

 

 

26

 

 

 

—

 

       Personnel-related

 

 

10,878

 

 

 

9,640

 

 

 

21,225

 

 

 

19,205

 

       Other(b)

 

 

4,133

 

 

 

4,484

 

 

 

8,276

 

 

 

9,435

 

Other income, net

 

 

1,885

 

 

 

1,556

 

 

 

2,799

 

 

 

3,417

 

Net loss

 

$

(25,005

)

 

$

(21,254

)

 

$

(48,521

)

 

$

(41,565

)

 

(a)
Other programs primarily include costs associated with AB-201.
(b)
Other primarily includes consultant, depreciation, rent, common area maintenance, lab supplies, legal, and insurance expenses.